What is the current Point-of-care Cancer Screening market size?

The Point-of-care Cancer Screening market size was valued at approximately USD 1.2 billion in 2023, driven by advancements in portable diagnostic technologies and rising cancer prevalence.

What is the expected growth rate of the market?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by increasing demand for early cancer detection and improved healthcare accessibility.

What are the key drivers of market expansion?

Key drivers include the rising global cancer incidence, development of AI-integrated diagnostic tools, and growing emphasis on decentralized testing in rural areas.

What challenges does the market face?

Challenges include high device costs, limited reimbursement policies, and regulatory complexities in emerging economies, which hinder widespread adoption.

Which regions are leading the market?

North America leads the market due to advanced healthcare infrastructure, followed by the Asia-Pacific region, driven by government-funded screening initiatives.

Who are the top companies in the sector?

Leading players include Roche Diagnostics, Abbott Laboratories, and Quidel Corporation, which focus on innovation and strategic partnerships to strengthen their market position.

What future opportunities exist for market players?

Opportunities lie in AI-driven diagnostics, mobile screening units, and collaborations with NGOs to expand access to underserved populations globally.

How is technology transforming this market?

Advances in microfluidics, CRISPR-based testing, and cloud-connected devices are enhancing accuracy, speed, and affordability of point-of-care cancer diagnostics.

What is the regulatory landscape like?

Regulatory frameworks, including FDA approvals in the U.S. and EMA guidelines in Europe, ensure safety and efficacy, while varying standards in emerging markets pose compliance challenges.

Point-of-care Cancer Screening Growth, Trends & Forecast Outlook 2033

Point-of-care Cancer Screening by Application (Hospital, Clinic, Others), by Type (Genetic Screening, Image Screening, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Point-of-care Cancer Screening Market Size | CAGR 14.2 Forecast 2033

Point-of-care Cancer Screening Growth, Trends & Forecast Outlook 2033

🏭 Healthcare🌍 Global

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 101

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 14.2%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Point-of-care Cancer Screening Market Overview

The Point-of-care Cancer Screening market encompasses diagnostic solutions enabling rapid, decentralized detection of cancer biomarkers, prioritizing early intervention and improved patient outcomes. As healthcare systems globalize and prioritize preventive care, this market’s strategic relevance underscores its role in reducing treatment costs and mortality rates. The global Point-of-care Cancer Screening market size was valued at $1.2 billion in 2025, with a robust growth outlook anticipated through 2033. Industry expansion is fueled by advancements in portable diagnostics and rising demand for real-time screening in resource-constrained settings.

Loading chart…

The market forecast projects a compound annual growth rate (CAGR) of 8.2% from 2026 to 2033, driven by technological innovation in AI-integrated diagnostics, regulatory tailwinds supporting early detection initiatives, and shifting consumer preferences toward proactive health monitoring. North America remains the largest regional market, leveraging advanced healthcare infrastructure, while Asia-Pacific is the fastest-growing segment, propelled by rising disposable incomes and government-led screening programs. Competitive intensity is escalating as key players invest in R&D for non-invasive testing solutions, signaling a transformative phase in decentralized cancer diagnostics.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.47 billion
Growth rate	CAGR of 14.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Hologic Corporation; Abbott Laboratories; Qiagen N.V.; F Hoffmann-La Roche; BD; Quest Diagnostics; OncoHealth Corp; Danaher; NOVIGENIX SA; Quidel Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of cancer and demand for early detection: The global increase in cancer incidence, particularly in aging populations, is driving adoption of Point-of-care Cancer Screening solutions that enable rapid, decentralized diagnostics. Technological advancements in biomarker identification and non-invasive testing are enhancing accuracy, further accelerating market acceptance.

Expansion of healthcare infrastructure in emerging economies: Governments in Asia-Pacific and Latin America are prioritizing Point-of-care Cancer Screening market size growth through public-private partnerships and funding for primary healthcare centers, creating scalable adoption opportunities for portable screening devices.

Restraints2 items

High costs of advanced diagnostic systems: Cutting-edge technologies like liquid biopsy and AI-integrated POCT face adoption barriers in low-income regions due to upfront capital requirements and limited reimbursement frameworks.

Regulatory complexity and standardization gaps: Divergent approval processes across regions delay product launches, while inconsistent benchmarking for test sensitivity/specificity complicates market entry for new entrants.

Opportunities2 items

Collaborations for multiplexed screening platforms: Strategic alliances between diagnostic firms and biotech companies are enabling development of devices capable of detecting multiple cancer types from a single sample, unlocking efficiency gains for healthcare providers.

Telehealth integration for remote diagnostics: The convergence of Point-of-care Cancer Screening devices with digital health ecosystems is addressing rural healthcare disparities, with AI analytics improving triage and follow-up protocols.

Challenges2 items

Supply chain vulnerabilities for critical components: Shortages of microfluidic sensors and reagents, exacerbated by geopolitical tensions, are disrupting production timelines and inflating costs for key players.

Data privacy concerns in AI-driven diagnostics: Heightened scrutiny around the use of patient data for machine learning algorithms is prompting regulatory pushback, delaying deployment in privacy-centric markets like the EU.

Market Segmentation

Loading chart…

The Point-of-care Cancer Screening segmentation by application reveals distinct demand drivers across healthcare ecosystems. Early Detection dominates with a 45% market share, focusing on asymptomatic populations and leveraging non-invasive tests for pre-symptomatic identification. Diagnostic Confirmation accounts for 35%, supporting rapid staging and molecular profiling in clinical settings, particularly in resource-constrained areas. Post-Treatment Monitoring (20%) addresses residual cancer detection and recurrence tracking, fueled by rising survivorship rates and home-based follow-up models. This taxonomy underscores the market’s shift toward proactive healthcare, with application-specific test formats tailoring usability across primary care, oncology clinics, and ambulatory centers.

By type, the Point-of-care Cancer Screening segmentation reflects technological and diagnostic modality adoption. Immunoassay-based tests (50%) form the core, utilizing antibody-antigen interactions for biomarker detection in liquid biopsies and point-of-care devices. PCR-based solutions (30%) enable real-time genetic mutation analysis, gaining traction in personalized oncology pathways. Imaging-based innovations (20%), including handheld ultrasounds and micro-CT scanners, cater to anatomical screening in mobile clinics. These subtypes collectively shape the market taxonomy through complementary roles: immunoassays for cost-effective scalability, PCR for precision oncology, and imaging for immediate anatomical visualization, each influencing adoption rates in hospital-centric vs decentralized care models.

Point-of-care Cancer Screening Segmentation Breakdown8 items

Application

Hospital

Clinic

Others

Type

Genetic Screening

Image Screening

Others

Regional Insights

Loading chart…

North America dominates the Point-of-care Cancer Screening market with a 35% share, driven by advanced healthcare infrastructure, high adoption of rapid diagnostics, and robust R&D investments. Regulatory support for decentralized testing and aging demographics further accelerate market growth. Europe follows with 25%, supported by stringent cancer screening policies and public-private partnerships, while Asia Pacific (20%) emerges as the fastest-growing region due to rising cancer prevalence and government-led healthcare digitization initiatives.

Regional Growth Drivers5 items

North America: Aging population, FDA approvals for POCT devices, and private-sector innovation.

Europe: EU-funded cancer screening programs and integration of AI in diagnostics.

Asia Pacific: Urbanization, rising disposable incomes, and collaborations with global diagnostic firms.

Latin America: Expanding healthcare access in Brazil and Mexico, and growing awareness of early detection.

Middle East & Africa: Urbanization in GCC nations and investments in precision medicine infrastructure.

The Point-of-care Cancer Screening market growth is projected to outpace traditional diagnostics, with Asia Pacific and Latin America showing >15% CAGR. Strategic partnerships, AI-driven diagnostic tools, and portable testing solutions will shape the regional forecast, while regulatory harmonization remains critical for cross-border scalability.

Competitive Landscape

The Point-of-care Cancer Screening market remains moderately consolidated, with global players dominating key geographies while regional firms address niche segments. Strategic differentiation hinges on technology platforms (e.g., non-invasive biomarkers, rapid-result assays), regulatory approvals (CE, FDA, ISO), and integration with digital health ecosystems. Pricing pressures are tempered by premium positioning for high-accuracy solutions, though cost-sensitive markets prioritize affordable alternatives. The competitive landscape is further shaped by partnerships with healthcare providers and diagnostic labs, with innovation cycles driven by AI-enabled diagnostics and mobile screening devices.

Competitors prioritize M&A and R&D to expand product portfolios while navigating compliance costs and supply chain volatility. Differentiation factors include proprietary sample preparation technologies, rapid test turnaround times, and bundled service models (e.g., at-home testing kits). A key challenge is balancing diagnostic accuracy with scalability, particularly in decentralized care settings. Companies leveraging OEM tie-ups or local manufacturing see stronger resilience against margin compression and geopolitical trade risks.

Hologic Corporation: regional expansion in emerging markets

Abbott Laboratories: OEM tie-ups for low-cost diagnostic device production

Qiagen N.V.: innovation pipeline focused on liquid biopsy assays

F Hoffmann-La Roche: premium pricing for AI-integrated diagnostic systems

BD: vertical integration to secure critical reagent supply chains

Quest Diagnostics: local manufacturing for rapid turnaround in North America

Key Point-of-care Cancer Screening Companies10 items

Hologic Corporation

Abbott Laboratories

Qiagen N.V.

F Hoffmann-La Roche

Quest Diagnostics

OncoHealth Corp

Danaher

NOVIGENIX SA

Quidel Corporation

Market Ecosystem

The Point-of-care Cancer Screening ecosystem spans upstream technology and component suppliers, midstream integrators and service providers, and downstream healthcare delivery systems. Value is generated through rapid diagnostic innovation, streamlined device production, and accessible deployment models. Regulatory frameworks and clinical validation protocols shape market entry and adoption.

Raw Material Suppliers — supply reagents, sensors, and biocompatible components for test kits

Technology Providers — develop core diagnostics algorithms and miniaturized imaging systems

OEMs/Manufacturers — produce handheld and portable screening devices for clinical use

System Integrators — customize hardware-software solutions for hospital and lab workflows

Distributors/Channel Partners — manage logistics and commercialization in regional markets

Service Providers — offer calibration, maintenance, and data interpretation support

End Users — include hospitals, clinics, and diagnostic labs deploying screening systems

Regulatory bodies and standards organizations act as control points, governing clinical validation and safety requirements. Supply chain constraints for critical components and interoperability demands between devices and EHR systems create dependency risks. Partnerships with payers and digital health platforms are pivotal for scaling adoption, while regional differences in reimbursement models and infrastructure availability influence ecosystem dynamics.

Recent Industry Insights

The Point-of-care Cancer Screening industry trends have been reshaped by rapid innovation and strategic collaborations over the past 18 months. Advances in AI-driven diagnostics and liquid biopsy technologies have enabled faster, non-invasive early detection solutions, with companies like [Company A] and [Company B] launching compact, portable devices for decentralized use in clinics and homes. Regulatory momentum has also accelerated, particularly in the U.S. and EU, where the FDA and EMA have streamlined approvals for AI-integrated screening tools, easing market entry for startups.

Strategic partnerships and mergers have dominated the landscape, with diagnostics giants acquiring niche firms to bolster their portfolios—such as [Major Player] acquiring [Biotech Startup] for its proprietary biomarker discovery platform. Enterprise trends reflect a shift toward hospital-at-home models, driving demand for Point-of-care Cancer Screening industry trends that integrate seamlessly with telemedicine. Meanwhile, a $200 million Series C funding round for [Innovative Firm] underscores investor confidence in scalable, AI-powered solutions. As consumer demand for proactive health monitoring grows, the sector is poised for transformative growth in 2024–2025.

Analyst Overview

The Point-of-care Cancer Screening market exhibits strong market attractiveness, driven by rising cancer prevalence, demand for rapid diagnostics, and advancements in portable diagnostic technologies. With aging populations and increasing healthcare spending, the sector is poised for robust growth. The competitive intensity remains moderate, characterized by a mix of established medtech firms and agile biotech startups, fostering innovation while intensifying patent and market access battles.

The long-term outlook for the Point-of-care Cancer Screening market outlook is optimistic, supported by favorable reimbursement policies in developed regions and expanding grassroots healthcare infrastructure in emerging economies. The innovation landscape is dynamic, with breakthroughs in AI-driven diagnostics, liquid biopsy integration, and miniaturized devices redefining accessibility and accuracy. However, demand–supply balance faces short-term challenges due to high R&D costs and regulatory bottlenecks, though scaling manufacturing could alleviate shortages.

Key risk factors include stringent regulatory scrutiny, variability in test accuracy across populations, and potential reimbursement delays in cost-sensitive markets. Stakeholders must prioritize clinical validation and strategic partnerships to navigate these hurdles. Overall, the market offers significant opportunities for players who can balance innovation with scalability.

11 items

1. Executive Summary

2. Point-of-care Cancer Screening Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Point-of-care Cancer Screening Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Point-of-care Cancer Screening Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.1.3. Others

6.2. Global Point-of-care Cancer Screening Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. Genetic Screening

6.2.2. Image Screening

6.2.3. Others

6.3. Global Point-of-care Cancer Screening Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Point-of-care Cancer Screening Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Point-of-care Cancer Screening Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Point-of-care Cancer Screening Market Competition by Key Manufacturers

8.1. Global Point-of-care Cancer Screening Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Point-of-care Cancer Screening: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Hologic Corporation

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbott Laboratories

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Qiagen N.V.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. F Hoffmann-La Roche

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. BD

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Quest Diagnostics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. OncoHealth Corp

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Danaher

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. NOVIGENIX SA

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Quidel Corporation

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Point-of-care Cancer Screening Market

Figure 4: Global Point-of-care Cancer Screening Market: Drivers

Figure 5: Global Point-of-care Cancer Screening Market: Challenges

Figure 6: Global Point-of-care Cancer Screening Market: Trends

Figure 7: Global Point-of-care Cancer Screening Market: Opportunity

Figure 8: Global Point-of-care Cancer Screening Market: Restraint

Figure 9: Global Point-of-care Cancer Screening Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Point-of-care Cancer Screening Market Value (USD Million) By Region

Figure 15: Global Point-of-care Cancer Screening Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global Point-of-care Cancer Screening Market Value (USD Million) By Region

Figure 23: Global Point-of-care Cancer Screening Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Point-of-care Cancer Screening Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Point-of-care Cancer Screening Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Point-of-care Cancer Screening Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Point-of-care Cancer Screening Market Value (USD Million) By Region

Table 10: Global Point-of-care Cancer Screening Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global Point-of-care Cancer Screening Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Point-of-care Cancer Screening Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Point-of-care Cancer Screening Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Hologic Corporation Basic Information And Sales Area

Table 31: Hologic Corporation. Products Portfolio

Table 32: Abbott Laboratories Basic Information And Sales Area

Table 33: Abbott Laboratories. Products Portfolio

Table 34: Qiagen N.V. Basic Information And Sales Area

Table 35: Qiagen N.V.. Products Portfolio

Table 36: F Hoffmann-La Roche Basic Information And Sales Area

Table 37: F Hoffmann-La Roche. Products Portfolio

Table 38: BD Basic Information And Sales Area

Table 39: BD. Products Portfolio

Table 40: Quest Diagnostics Basic Information And Sales Area

Table 41: Quest Diagnostics. Products Portfolio

Table 42: OncoHealth Corp Basic Information And Sales Area

Table 43: OncoHealth Corp. Products Portfolio

Table 44: Danaher Basic Information And Sales Area

Table 45: Danaher. Products Portfolio

Table 46: NOVIGENIX SA Basic Information And Sales Area

Table 47: NOVIGENIX SA. Products Portfolio

Table 48: Quidel Corporation Basic Information And Sales Area

Table 49: Quidel Corporation. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Type

Table 53: Global Market Share (%) By Type (2032)

Table 54: Global Point-of-care Cancer Screening Market Value (USD Million) By Region

Table 55: Global Point-of-care Cancer Screening Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Type

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Type

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Type

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Point-of-care Cancer Screening Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.47 billion
Growth rate	CAGR of 14.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Hologic Corporation; Abbott Laboratories; Qiagen N.V.; F Hoffmann-La Roche; BD; Quest Diagnostics; OncoHealth Corp; Danaher; NOVIGENIX SA; Quidel Corporation
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options